Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New online CBT shows promise for anxious kids and teens

NCT ID NCT06661460

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is developing and testing a new internet-delivered cognitive behavioral therapy (ICBT) program for children and teens aged 8-17 with anxiety disorders. The 12-week program, guided by a therapist, uses exposure therapy to help young people face their fears. Researchers will measure changes in anxiety severity and gather feedback to improve the treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
internet-delivered cognitive behavioral therapy (ICBT)
What this could lead to
If it works, this could provide an effective, accessible treatment option for young people with anxiety disorders, reducing symptoms and improving daily life.
What could go wrong
This is a small, early-stage open trial with no control group, so results may not be definitive. The intervention may not work for all types of anxiety or may require further refinement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

8 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1\) 8 to \<18 years of age. * Confirmed by the child/caregiver and subsequently by the medical record system. 2) A principal DSM-5-TR anxiety disorder of specific phobia, separation anxiety disorder, social anxiety disorder, generalized anxiety disorder, panic disorder or agoraphobia. * Confirmed by the Diagnostic Interview for Anxiety, Mood, and OCD and related Neuropsychiatric Disorders - Child and Adolescent Version (DIAMOND-KID). 3\) Child and caregiver able to read, write and communicate in Swedish. * Confirmed by the child/caregiver. 4) An available caregiver who can support the child in treatment. * Confirmed by the caregiver. 5) Access to a smartphone, tablet, or laptop/desktop device, and the internet. * Confirmed by the child/caregiver. Exclusion Criteria: 1\) Principal DSM-5-TR anxiety disorder of specific phobia concerning the domain of blood-injection-injury (due to the ICBT program not including relevant information on applied-tension techniques to avoid fainting during exposure exercises). * Confirmed by a blood-injection-injury phobia being classified as the principal anxiety disorder as assessed by the DIAMOND-KID. 2\) Established or suspected intellectual disability. * Confirmed by the caregiver (through previous diagnosis) and/or by attending a special needs school for learning difficulties. 3\) Another mental disorder in more immediate need of management than an anxiety disorder (e.g., schizophrenia spectrum and other psychotic disorders, bipolar disorder, anorexia nervosa, substance use disorders). * According to the DIAMOND-KID and/or other available sources. 4) Social/familial/educational difficulties in more immediate need of management than an anxiety disorder. * Confirmed by the assessor through information from the child/caregiver and/or other available sources. 5\) Immediate risk to self or others that require urgent attention, such as acute suicidality. * Confirmed by the assessor through information from the child/caregiver and other available sources. 6\) Previous CBT for an anxiety disorder, defined as five or more sessions with a certified CBT therapist within the 12 months prior to assessment. * Confirmed by the child/caregiver or the medical record system. 7) Ongoing psychological treatment for an anxiety disorder. * Confirmed by the child/caregiver or the medical record system. 8) Initiation or adjustment of any psychotropic medication for anxiety (i.e., selective serotonin reuptake inhibitors, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitor or antipsychotics) within 8 weeks prior to assessment. * Confirmed by the child/caregiver or the medical record system. 9) Participation in user involvement sessions in the present study. * Confirmed by the researcher.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Agoraphobia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Barn- och ungdomshälsan, Länssjukhuset

    RECRUITING

    Kalmar, Region Kalmar Län, 391 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.